Ovarian Cancer | Topics

Phase 2 DeCidE1 Trial Reports Final Topline Results on the Efficacy of Maverpopepimut-S in Advanced Recurrent Ovarian Cancer
August 20, 2021

The topline results from the DeCidE1 trial showing promising results for patients with ovarian cancer treated with maverpopemiut-S.

FDA Grants Fast Track Designation to STRO-002 in Select Patients With Advanced Ovarian Cancer
August 18, 2021

The folate receptor α–targeting antibody-drug conjugate STRO-002 has a fast track designation from the FDA for advanced, platinum-resistant ovarian cancer following 1 to 3 prior lines of therapy.

FDA Grants Fast Track Designation to IN10018 for Platinum-Resistant Ovarian Cancer
August 16, 2021

The FDA has granted IN10018 a fast track designation for the treatment of patients with platinum-resistant ovarian cancer.